N-(2,6-dimethylphenyl)-3-[6-(4-t-butylphenylsulfonylamino)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyloxy]propionamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-(2,6-dimethylphenyl)-3-[6-(4-t-butylphenylsulfonylamino)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyloxy]propionamide
• 英文别名: 3-[6-[(4-Tert-Butylphenyl)sulfonylamino]-5-(2-Methoxyphenoxy)-2-Pyrimidin-2-Yl-Pyrimidin-4-Yl]oxy-N-(2,6-Dimethylphenyl)propanamide；3-[6-[(4-tert-butylphenyl)sulfonylamino]-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]oxy-N-(2,6-dimethylphenyl)propanamide
• 化学式: C₃₆H₃₈N₆O₆S
• 分子量: 682.8
• InChiKey: MTNFANNLCUMCNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  49
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  163
• 氢给体数：
  2
• 氢受体数：
  11

文献信息

• Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy
  申请人：Amberg Wilhelm

  公开号：US20090311266A1

  公开（公告）日：2009-12-17

  The invention relates to the use of an endothelin blocker in combination with an α v β 3 integrin receptor antagonist for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising an endothelin blocker and an α v β 3 integrin receptor antagonist, for the treatment or prevention of cardiovascular disorders, particularly for the treatment or prevention of restenosis after vessel injury or revascularisation treatment and to the pharmaceutical composition itself.

  本发明涉及将内皮素阻滞剂与αvβ3整合素受体拮抗剂结合使用以治疗或预防疾病，特别是涉及使用一种制药组合物，包括内皮素阻塞剂和αvβ3整合素受体拮抗剂，用于治疗或预防心血管疾病，特别是用于治疗或预防血管损伤或再血管化治疗后的再狭窄，以及该制药组合物本身。
• PYRIMIDINE DERIVATIVES
  申请人：KOWA CO. LTD.

  公开号：EP0801062A1

  公开（公告）日：1997-10-15

  The present invention is directed to a pyrimidine derivative of the following formula (1) or a salt of the derivative: [wherein R1 represents a lower alkyl group; each of R2 and R3 represents H, alkyl, or alkoxy; each of R4 and R5 represents H or alkyl; R6 represents alkyl, -OR7, or -NR8R9; and n is a number between 0 and 3 inclusive (wherein each of R7, R8, and R9 represents H, alkyl, aryl, aralkyl, amino, a heterocyclic ring, etc.)], as well as to a medicine containing the derivative or salt as the active ingredient. The present compounds exhibit strong binding inhibitory activity against endothelin having potent vasoconstrictive effect and cell proliferation effect. Therefore, the compounds are effective as remedies for various diseases including circulatory diseases.

  本发明涉及下式（1）的嘧啶衍生物或该衍生物的盐： [其中 R1 代表低级烷基；R2 和 R3 各代表 H、烷基或烷氧基；R4 和 R5 各代表 H 或烷基；R6 代表烷基、-OR7 或 -NR8R9；n 为 0 至 3 之间的数字（其中 R7、R8 和 R9 各代表 H、烷基、芳基、芳烷基、氨基、杂环等）]，以及含有该衍生物或盐作为活性成分的药物。本化合物对内皮素具有很强的结合抑制活性，具有很强的血管收缩效应和细胞增殖效应。因此，这些化合物可有效治疗包括循环系统疾病在内的各种疾病。
• US6008224A
  申请人：——

  公开号：US6008224A

  公开（公告）日：1999-12-28
• US6337334B1
  申请人：——

  公开号：US6337334B1

  公开（公告）日：2002-01-08